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INTRODUCTION 
 
 Diabetes mellitus is a group of metabolic disease characterized by 
hyperglycaemia resulting from defects in Insulin secretion, Insulin action 
or both1. It is a complex disease where carbohydrate, protein and fat 
metabolism is impaired2. 
 
 Diabetes is an “ice berg” disease. The number of cases of diabetes 
world wide is estimated to be around 150 million. It is estimated that 20 
percent of the current global diabetic population resides in South- East 
Asia Region.  
  
 In India, the prevalence of disease in adults was found to be 2-4 
percent in rural and 4 – 11.6 percent in urban dwellers. High frequencies 
of impaired glucose tolerance, shown by studies ranging from 3.6-9.1 
percent indicate the potential for further rise in prevalence of DM in the 
coming decades3.  
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CLASSIFICATION4   
Type 1 Diabetes 
A. Immune mediated 
B. Idiopathic 
 
Type 2 Diabetes 
 Other specific types 
 Gestational Diabetes Mellitus (GDM) 
 Impaired Glucose Tolerance (IGT)  
 
 IDDM onset is typically abrupt5 and is usually seen in individual 
less than 30 years. Immune mediated and β cells of pancreas are 
destroyed, usually associated with ketosis, Exogenous insulin is required 
to reverse the catabolic state. NIDDM is more common than IDDM, 
gradual in onset and occurs mainly in the middle aged and elderly3.  
 
 Diabetes is better known for its complications affecting the 
vascular system, kidney, retina, lens, peripheral nerves and skin which are 
extremely costly in terms of longevity and quality of life6.  
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 Lipid peroxidation is elevated in Diabetes7. Diabetes is usually 
accompanied by increased production of free radicals or reactive oxygen 
species7 which produces oxidative stress. The occurrence of free radical 
induced lipid peroxidation causes considerable change in the cell 
membrane8. Peroxidation of Lipid membrane has been related to the 
pathogenesis of many degenerative diseases such as Atherosclerosis9. 
Atherosclerosis is the most common complication of diabetes10. 
 Free radicals damage lipids by initiating a process called Lipid 
peroxidation11. 
 The decomposition of lipid peroxides forms many cytotoxic 
compounds like malondialdehyde(MDA). 
 So oxidative stress can be measured by monitoring the changes in 
malondialdehyde6,7. Degree of lipid peroxidation was measured in terms 
of MDA. 
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AIM OF THE STUDY  
 
1. To study the level of lipid peroxide in IDDM and NIDDM. 
  
2. To find out the correlation between Lipid peroxide and Lipid 
profile in both types of diabetes mellitus. 
 
3. To find out the correlation between lipid peroxide with glycaemic 
control (HbA1C) 
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REVIEW OF LITERATURE 
 
 Diabetes was described more than 2000 years ago. Aretaeus of 
Cappadocia (about 150 AD) described the disease and referring to the 
polyuria, gave the name ‘DIABETES’ which comes from the Greek word 
meaning “To run through” (Dia-Through, Bainein-To go) because he 
observed that the disease consisted of “a liquefaction of flesh and bone in 
to urine”. 
 
 In 1674, Thomas Willis discovered (by tasting) that the urine of 
diabetic person was sweet, “As if imbued with honey (MELLITUS).” 
 
 Long before the discovery of insulin, physicians noticed that 
patients with diabetes fall into two clinical categories, young patients 
with  an intolerable thirst and rapid weight loss. In contrast, older patients 
often over weight, presented with milder symptoms and could survive for 
many years with careful diet. In the 1930’s Himsworth12 observed that 
young thin patients were sensitive to the action of injected insulin, where 
as older and fatter patients were not. From this he currently inferred that 
one type of diabetes was due to insulin deficiency and other to insulin 
 6
insensitivity. The term type 1 and type 2 were introduced by Lister13 in 
1951. 
 
 Diabetes mellitus is a clinical syndrome characterized by 
hyperglycaemia due to absolute or relative deficiency of Insulin. Lack of 
insulin affects metabolism of carbohydrate, protein and fat14. 
 
AETIOLOGICAL CLASSIFICATION OF DM15 
I. Type 1 DM 
a. Immune mediated – Type1A 
b. Idiopathic – Type1B. 
II. Type 2 DM 
III. Other specific types 
A. Genetic defects in β cell function 
1. MODY 1,2,3,4,5,6. 
2. Mitochondrial DNA mutation. 
3. Proinsulin to insulin conversion defect 
B. Genetic defects in Insulin action 
1. Type of insulin resistance 
2. Lipodystrophy 
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C. Diseases of the exocrine pancreas 
Pancreatitis, Pancreatectomy. 
Neoplasia, cystic fibrosis 
Haemochromatosis, Fibrocalcific Pancreatopathy. 
 
D. Endocrinopathies 
Acromegaly, Cushing’s Syndrome 
Glucagonoma, Pheochromocytoma 
Hyperthyroidism 
 
E. Drugs or chemical induced 
β adrenergic agonist 
β blocker, Glucocorticoids 
Pentamidine, Phenytoin, 
Protease inhibitor, Thyroid hormone 
Thiazides. 
 
F. Infections 
Congenital Rubella, Cytomegalovirus 
 
G. Uncommon forms of Immune mediated diabetes 
Anti-Insulin receptor Ab 
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H. Other genetic syndrome associated with DM 
Downs, Klinefelter’s, Turner’s , 
Wolf syndrome, Friedreich’s ataxia, Huntington’s chorea, 
Porphyria. 
IV. GDM  
 
Type I DM 
     IDDM (Insulin Dependent Diabetes Mellitus) 
 Caused by deficiency of pancreatic β cells. Usually results from an 
auto immune response that selectively destroys pancreatic β cells16. 
Frederick Banting & Charles Best first demonstrated in 1921; that daily 
insulin injection to is required to survive in IDDM17. There are two types,  
one is immune mediated & other is idiopathic18. 
 
NIDDM (Non Insulin Dependent Diabetes Mellitus) 
 Unlike IDDM this is relatively common in all populations enjoying 
an affluent life style. The disease may be present in a subclinical form for 
years before diagnosis and the incidence increase markedly with age and 
degree of obesity. The onset may be accelerated by stress of pregnancy, 
drug treatment or intercurrent illness19. Insulin resistance is considered as 
an important pathophysiological defect in the development of type 2 
diabetes20,21 along with β cell function22. 
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 Blood glucose concentrations are maintained within normal limits 
in healthy people by insulin. This insulin is secreted from β cells of 
pancreas. 
 
Circulating glucose derived from three main sources. 
1. The gut, as a result of hydrolysis or hepatic conversion of a 
variety of ingested carbohydrates. 
2. Hepatic and some other glycogen stores (Glycogenolysis). 
3. New synthesis from precursors (Gluconeogenesis). 
 
Insulin Secretion and action11      
 Glucose concentration is the key regulator of insulin action. 
 The principal antihyperglycaemic actions of insulin are 
a) Insulin reduces the production of gluconeogenic precursors such as 
glycerol, alanine and lactate 
b) reduces activity of hepatic gluconeogenic enzyme. 
c) increases hepatic glycogenolysis to glucose. 
d) reduced hepatic glucose output. 
e) increase cellular glucose uptake mediated by GLUT4. 
f) reduces competition for glucose oxidation by alternative fuels. 
g) initiation of NEFA release from adipose tissue. 
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h) reduces hepatic ketogenesis. 
i) insulin promotes glucose storage as glycogen. 
 
In diabetes due to deficiency of insulin, despite high blood glucose 
levels, cells ‘starve’ since insulin stimulated glucose entry into cells is 
impaired. TAG hydrolysis, FA oxidation, gluconeogenesis and ketone 
body formation are accelerated17. 
 
METABOLIC DEFECTS IN DIABETES  
Lack of insulin leads to mobilization of substances for 
gluconeogenesis and ketogenesis from muscle and adipose tissue, 
accelerated production of glucose and ketone by the liver and impaired 
removal of endogenous and exogenous fuels by insulin responsive 
tissues. The net results are severe hyperglycaemia and hyperketonemia 
that overwhelm renal removal mechanism23.      
 
Insulin affects many sites of mammalian lipids metabolism. It 
stimulates synthesis of FA in liver, adipose tissue and in the intestine. 
Insulin increases cholesterol synthesis and the activity of lipoprotein 
lipase activity in white adipose tissue is increased24.    
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DYSLIPIDAEMIA IN DM 
Common form of dyslipidaemia in DM is that hypertriglyceridaemia with 
reduced HDL levels 25  
 
 Once diabetes has developed, increased concentrations of LDL 
cholesterol and decreased concentrations of HDL cholesterol appear. 
Elevated serum triglycerides with low HDL cholesterol and increased 
LDL are common in type 2 diabetic patients without significant 
hypercholesterolemia26. 
 
 In diabetes due to absence of insulin, hormone sensitive lipase is 
activated, more FFA are formed, these are catabolised to produce acetyl 
COA. As available oxaloacetate is less, acetyl COA is not readily 
utilized. So increased Acetyl COA is channelled to cholesterol synthesis 
leading to increased serum cholesterol levels27. 
 
 Hormone sensitive lipase hydrolyses triglycerides to glycerol and 
fatty acids28. The activity of endothelial insulin dependent lipoprotein 
lipase activity is less resulting in diminished triglyceride clearance from 
triglyceride rich lipoproteins. This results in hypertriglyceridemia. 
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 The low lipoprotein lipase activity results in impaired lipolysis of 
VLDL and reduced formation of HDL particles29. 
 
OXIDATIVE STRESS IN DM 
 
Lipid peroxidation is elevated in diabetes30. Diabetes mellitus is 
considered to be rank one of free radical disease which propagates 
complications with increased free radical formation. Lipid peroxides are 
non-radical intermediates derived from unsaturated fatty acids, 
phospholipids, glycolipids, cholesterol esters and cholesterol. This 
formation occurs in enzymatic or non-enzymatic reactions involving 
activated chemical species known as “reactive oxygen species” (ROS) 
which are responsible for toxic effects in the body via various tissue 
damages. 
 
 Excessively high levels of free radicals cause damage to cellular 
proteins, membrane lipids and nucleic acids and eventually cell death. 
 
 Glucose oxidation is the main source of free radicals. Glucose in its 
enediol form is oxidized in a transition-metal dependent reaction to an 
enediol radical anion that is converted into reactive ketoaldehydes and to 
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superoxide anion radicals. The superoxide anion radicals undergo 
dismutation to hydrogen peroxide. 
 
 H2O2 if not degraded by catalase or glutathione peroxidase and in 
the presence of transition metals, can lead to production of extremely 
reactive hydroxyl radicals. 
 
Hyperglycaemia also promotes lipid peroxidation of LDL by 
superoxide dependent pathway resulting in the generation of free radicals. 
 
Damage to protein is important because it affects the function of 
receptors, enzymes, transport proteins and by generating new antigen that 
provokes immune responses29.  
 
Glucose interacts with protein leading to the formation of an 
amadori product and advanced glycation end products(AGE). AGEs via 
their receptors inactivate enzymes, alter their structure and function and 
promote free radical formation. 
 
Prolonged oxidative stress can lead to depletion of essential 
antioxidants31,32.         
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Imbalance between protective antioxidants and increased free 
radical production leading to oxidative damage is known as oxidative 
stress33. 
 
Lipid peroxidation is the free radical damage of lipids. 
 
During lipid peroxidation of polyunsaturated fatty acids MDA is 
formed, by the action of human platelet thromboxane synthetase on 
prostaglandins PGH2, PGH3 and PGG2, and by the action of polyamine 
oxidase and  amine oxidase on spermine. 
 
MDA is a dialdehyde and is a very reactive molecule. Under 
physiological conditions MDA exists as an enolate anion( O—CH=CH—
CHO), a form that is only fairly reactive, forming Schiff base with 
molecules containing a free amine group. Under more acidic conditions( 
PH<4), beta hydroxyacrolein (HO—CH=CH—CHO) is the predominant 
form. Beta hydroxyacrolein is a very reactive electrophile capable of 
reacting in a Michael addition with a number of biologically important 
nucleophiles. Proteins are more reactive with MDA than free aminoacids 
forming a variety of adducts and cross-links. MDA can also react with 
DNA bases producing a variety of mutagenic compounds. MDA has the 
potential to induce amino-imino-propen cross-links between 
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complimentary strands of DNA and can also cause the formation of 
DNA- protein cross-links. 
 
MDA is metabolized in the liver to malonic acid semialdehyde. 
This is unstable and spontaneously decomposes to acetaldehyde that is 
then converted to acetate by aldehyde dehydrogenase and inally to carbon 
dioxide and water. Some MDA eventually ends up as acetyl-CoA. 
Mammalian urine also contains enaminals derived from the hydrolysis of 
MDA modified proteins. 
 
  
(1,1′,3,3′ Tetramethoxy propane) 
 
     MDA is used as an index of oxidative stress and is a marker of lipid 
oxidation33-36. Lipid peroxidation is important because it contributes to 
the development of atherosclerosis37-39.  
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The study is undertaken to evaluate the relationship of lipid 
peroxide with lipids, lipoprotein fractions in IDDM and NIDDM to find 
the possibilities of preventing complications.     
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MATERIAL AND METHODS 
  
 Participants of the study group were selected from the outpatients 
population of Department of Diabetology, Thanjavur Medical College, 
Thanjavur. 
 
 100 patients were selected for this study. Out of which 50 patients 
belong to NIDDM and 50 to IDDM group. 
 
 50 persons served as healthy control. 
 
INCLUSION CRITERIA  
 All ambulatory NIDDM and IDDM patients without any 
complications. 
EXCLUSION CRITERIA : 
 Smokers  
 Alcoholics 
 Renal failure 
 Bronchial Asthma 
 History Suggestive of Complications of DM 
- Angiopathy 
- Cardiopathy 
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- Retinopathy 
- Nephropathy 
Detailed history and complete clinical examination was done in all 
the cases. 
 
 For all the patients, fasting and post prandial blood samples and 
fasting urine samples were collected. For blood sugar estimation, blood 
collected in fluorinated tube. For other investigations in plain tube 
samples were collected.  
The following investigations were done. 
1. Serum malondialdehyde. 
2. Blood sugar 
a. Fasting 
b. Post prandial 
3. HbA1C 
4. Serum Lipid profile 
5. Blood urea 
6. Serum Creatinine 
7. Urine Albumin & Sugar 
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ESTIMATION OF PLASMA TBARS 
 
 
 
METHODOLOGY: 
 
 
 METHOD OF YAGI 
 
 
PRINCIPLE: 
 
 
 Reaction of MDA with Thiobarbituric acid (TBA) yields a red 
MDA-TBA adduct. The product of 2 mol of TBA plus 1 mol of MDA. 
The coloured complex is readily extractable into organic solvents such as 
Butanol. Quantification is done spectrophotometrically at 532 nm. 
 
 
 
 
 
REAGENTS: 
   
1. Sulphuric acid 0.083 N 
2. Phosphotungstic acid 10% 
3. n Butanol 
4. Thiobarbituric acid 670 mg is dissolved in 100ml of water. To this 
100 ml of acetic acid is added. 
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5. Standard stock solution (1,1′,3,3′ Tetramethoxy propane 
(84mg/ml)) 
 
 
PROCEDURE: 
 
 To 0.5ml of plasma, 4ml of 0.083N sulphuric acid is added. To this 
mixture 0.5ml of 10% phosphotungstic acid is added and mixed, allowed 
to stand at room temperature for 5 minutes. The mixture is centrifuged at 
3000 rpm for 10 minutes. The supernatant is discarded. To the remaining,  
1 ml of TBA is added. The reaction mixture is heated at boiling water 
bath for 60 mts. After cooling, mixture is centrifuged at 3000 rpm for 15 
mts. Supernatant is transferred to cuvette. 
  
 Standard MDA solutions are  2 μmol/L, 4 μmol/L, 6 μmol/L, 
8μmol/L & 10 μmol/L and a blank were processed along with the test 
sample. 
 
 The absorbance at 530 nm was measured and subtracted from the 
blank. A calibration graph was prepared using MDA standard. 
 
Reference Range: 
 
Serum / Plasma MDA  
 
 0.03 to 3.88 μmol/L 
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GLYCOHEMOGLOBIN 
 
METHODOLOGY: 
 
 Ion exchange resin method 
                                 
 
PRINCIPLE  
 
 A haemolysed preparation of the whole blood is mixed 
continuously for 5 minutes with a weak binding cation-exchange resin. 
During this time, HbAo binds to the resin. After the mixing period, a 
filter is used to separate the supernatant containing the glycohaemoglobin 
from the resin. 
 
 Haemolysed            Cation 
 
Whole blood     +    Exchange   ⎯⎯⎯⎯⎯ →⎯ minutes 5for  Mix    Fast Fractions  
                                                                             (HbA1a, HbA1b, HbA1c)       
Preparation              Resin 
 
 
 The Glycohaemglobin percent is determined by measuring the 
absorbance’s at 415 nm of glycohaemoglobin fraction and the total 
hemoglobin fraction. The ratio of the two absorbances gives the 
percentage Glycohaemoglobin. 
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REAGENT COMPOSITION 
 
 
REAGENT 1: GLYCOHAEMOGLOBIN ION EXCHANGE RESIN    
 
Cation – Exchange Resin (pH 6.9) 8 m g / m l 
 
 
REAGENT 2: GLYCOHAEMOGLOBIN LYSING REAGENT 
 
Lysing Reagent 10 m M 
 
REAGENT 3: GLYCOHAEMOGLOBIN CALIBRATOR  
 
Calibrator 10% 
  
 
REAGENT RECONSTITUTION 
 
1. Glycohaemoglobin Ion Exchange Resin 
 The ion exchange resin is ready for use and prefilled in plastic 
tubes. 
2. Glycohaemoglobin Lysing Reagent  
  The reagent is ready for use. 
3. Glycohaemoglobin Calibrator     Glycohemoglobin Calibrator is 
allowed to attain the room temperature. 
The contents of each vial is dissolved in 1 ml of deionised water 
free of contaminants. 
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ASSAY PROCEDURE 
STEP 1: HAEMOLYSATE PREPARATION 
 
 CALIBRATOR TEST 
Lysing Reagent 500 μl 500 μl 
Calibrator 100 μl -- 
Sample / Whole 
Blood -- 100μl 
 
STEP II: SEPARATION OF GLYCOHEMOGLOBIN 
1.  0.1ml of the haemolysate is added from STEP 1 into the 
appropriately marked Ion-Exchange Resin tubes. 
2. The filter separator is positioned approximately 2 cm above the 
liquid level in the tube. 
3. The tubes are placed  on the shaker and allowed to mix 
continuously for 5 minutes. 
      4.  The tubes are removed from the shaker. 
 5.  The filter separator is pushed until the resin is firmly packed. 
 6.  The supernatant of each tube is poured  into appropriately marked  
tubes. 
     7.   Absorbance of each tube for Glycohaemoglobin at 415nm 
(450nm-420nm)  against deionised water blank is read and 
recorded. 
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STEP III: TOTAL HAEMOGLOBIN FRACTION     
 
The reading of analyzer is set to with deionised water. 
 
 CALIBRATOR TEST 
Deionised water 5.0 ml 5.0 ml 
Calibrator 
Haemolysate 20 μl -- 
Sample Haemolysate -- 20μl 
 
 Mixed well, read and recorded the absorbance of calibrator, and 
sampled against a deionised water blank at 415 nm (405nm-420nm) for 
Total Haemoglobin readings. 
 
CALCULATION  
 
 The ratio (R) of the Glycohaemoglobin absorbance to the total 
haemoglobin absorbance is calculated. The following equations are used 
to determine unknown concentrations. 
(Total) Calibrator of Absorbance
(Glyco) Calibrator of Absorbance  Rc =   
 
 
(Total) Unknown of Absorbance
(Glyco) Unknown of Absorbance Ru =  
 
Calibrator of  x value
Rc
Ru unknown  ofglobin Glycohaemo % =  
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LINEARITY 
  
 The assay is linear upto 20% for glycohaemoglobin levels. For 
blood samples with total haemoglobin greater than 18g/dl sample should 
be diluted with deionised water before the assay. 
 
NORMAL VALUES (Reference for guidelines) 
 
 A1 A1c 
NORMAL 6.0% - 8.3% 4.3% - 6.2% 
GOOD DIABETIC 
CONTROL 7.5% - 9.0% 5.5% - 6.8% 
FAIR CONTROL 9.0% - 10.0% 6.8% - 7.6% 
POOR CONTROL > 10% > 7.6% 
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METHODOLOGY 
 
DETERMINATION OF GLUCOSE IN SERUM  
GLUCOSE OXIDASE  / PEROXIDASE  METHOD 
PRINCIPLE 
 Glucose is oxidized to gluconic acid and hydrogen peroxide in the 
presence of glucose oxidase. Hydrogen peroxide further reacts with 
phenol and 4-aminoantipyrine by the catalytic action of peroxidase to 
form a red coloured quinoneimine dye complex. Intensity of the colour 
formed is directly proportional to the amount of glucose present in the 
sample. 
OH  Gluconate  OHO  Glucose 2
Oxidase
Glucose
22 +⎯⎯ →⎯++  
H2O2 + 4 Aminoantipyrine + Phenol ⎯⎯⎯ →⎯Peroxidase Red Quinoneimine dye + H2O 
 
Contents 
 L1 : Glucose reagents; 4x250 ml 
 L2 : Buffer reagent : 10ml 
 S : Glucose standard (100 mg/dl): 5ml 
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Reagent preparation:  
 2.5ml of Buffer reagent (L2) was added to 250ml of distilled water. 
 The contents of one bottle of glucose reagent (L1) was emptied 
into it, and mixed by gentle swirling and allowed to stand at room 
temperature for 30 minutes. This working reagent is stable for 60 days 
when stored at 2-8° C. 
SAMPLE MATERIAL – Serum 
 
PROCEDURE 
Wave length / Filter: 505 nm to 546 nm Green 
Temperature: 37° C/RT 
Light path: 1 cm 
The working reagent, distilled water, standard and sample were 
pipetted into clean dry test tube labeled as Blank (B), Standard (S), and 
Test (T) as follows: 
Addition 
Sequence B (ml) S (ml) T (ml) 
Working 
Reagent 1.0 1.0 1.0 
Distilled water 0.01 --- --- 
Glucose standard --- 0.01 --- 
Sample --- --- 0.01 
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Mixed well and Incubated at 37° C for 10 minutes. The absorbance 
of the standard (Abs. S) and Test sample (Abs. T) were measured against 
the blank, within 60 minutes at 505 nm. 
Calculations: 
Total glucose in mg/dl = 100 
Abs.S
Abs.T ×  
Linearity:  
  This procedure is linear up to 500 mg/dl. 
General system parameters 
 Reaction Type  : Endpoint 
 Reaction Slope  : Increasing 
 Wavelength   : 505nm 
 Incubation Temp  : 37°C/R.T 
 Sample Vol   : 10μL 
Reagent Vol   : 1.0mL 
Std. Concentration  : 100 mg/dL 
Zero Setting With  :  Reagent Blank 
Linearity   : 500 mg/dl 
Reference value  
Serum: Fasting 70-110 mg/dl 
Post Prandial: <140 mg/dl 
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ESTIMATION OF CHOLESTEROL 
ENZYMATIC METHOD PRINCIPLE 
Cholesterol Ester + H2O ⎯⎯⎯ →⎯Esterease
lCholestero
 Cholesterol + Fatty Acids 
Cholesterol + O2 ⎯⎯⎯ →⎯Oxidase
lCholestero
Cholest-4-en-3-one + H2O2     
2H2O2 + Phenol + 4-Aminoantipyrine ⎯⎯⎯ →⎯Peroxidase Red quinone + 4-H2O 
 
 The concentration of Cholesterol in the sample is directly 
proportional to the intensity of the red complex (Red Quinone) which is 
measure at 500 nm. 
 
REAGENTS    
Reagent 1 (Enzymes / Chromogen) 
 Cholesterol Esterease  ≥ 200 U/L 
 Cholesterol Oxidase  ≥ 250 U/L 
 Peroxidase    ≥ 1000 U/L 
 4-Aminoantipyrine  0.5 mmol/L 
Reagent 1A (Buffer):  
 Pipes buffer, pH 6.90  50 mmol/L 
 Phenol    24 mmol/L 
 Sodium Cholate   0.5 mmol/L 
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Standard (Cholesterol 200 mg/dL): 
 Cholesterol     2 g/L  
STORAGE & STABILITY OF THE REAGENTS   
 When stored at 2° C - 8° C and protected from light, the reagents 
are stable until the expiry dates stated on the labels. 
 
REAGENT RECONSTITUTION   
 The reagents are allowed to attain room temperature. The contents 
of one bottle of reagents 1 were dissolved with one bottle of reagent 1A 
and mixed by gentle swirling. 
 
RECONSTITUTED REAGENT STORAGE & STABILITY   
 The reconstituted reagent is stable for 3 months when stored at 2° 
C - 8°C. 
 
PROCEDURE   
 The samples and the reconstituted reagent were brought to room 
temperature prior to use. 
The following general system parameters were used with this kit: 
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General system parameters 
 Reaction Type  : Endpoint 
 Reaction Slope  : Increasing 
 Wavelength   : 500 nm (492-550) 
 Flowcell Temp  : 30° C 
 Incubation   : 5 Min. at 37°C 
 Sample Vol   : 10 μL 
 Reagent Vol   : 1.0 mL 
 Std. Concentration  : 200 mg/dL 
 Zero Setting With  : Reagent Blank 
The instrument was set using above system parameters. 
The reconstituted reagent, standard and the sample were dispensed 
in to test tubes as follows. 
 Blank Standard Test 
Reconstituted 1 mL 1 mL 1 mL 
Standard - 10 μL - 
Sample - - 10 μL 
     
 Incubated for 5 minutes at 37° C, mixed and read at 500 nm. 
Linearity: 
 The method is linear up to 500 mg/dL 
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Reference value for Cholesterol  
 Serum / Plasma: Male = < 220 mg / dL  
     Female = < 200 mg / dL 
 
ESTIMATION OF TRIGLYCERIDES 
ENZYMATIC COLORIMETRIC METHOD  
PRINCIPLE 
Triglycerides + H2O ⎯⎯⎯ →⎯Lipase
nLipoprotei
Glycerol + Fatty Acid 
Glycerol + ATP ⎯⎯ →⎯Kinase
 Glycerol
Glycerol-3-Phosphate + ADP 
Glycerol-3-Phosphate+O2 ⎯→⎯GPO Dehydroxyacetone Phosphate + H2O2 
2H2O2 + 4-Aminoantipyrine + ADPS ⎯⎯⎯ →⎯Peroxidase Red quinine + 4H2O 
GPO – Glycerol – 3-phosphate oxidase 
ADPS - N-Sulfopropyl-n-anisidine 
 
 The intensity of purple coloured complex formed during the 
reaction is directly proportional to the Triglycerides concentration in the 
sample and is measured at 546 nm. 
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REAGENTS 
Reagent 1 (Enzymes / Chromogen) 
  Lipoportein Lipase  ≥ 1100 U/L 
 Glycerol Kinase   ≥ 800 U/L 
 Glycerol-3-Phosphate Oxidase ≥ 5000 U/L 
 Peroxidase    ≥ 350 U/L 
 4-Aminoantipyrine  0.7 mmol/L 
 ATP     0.3 mmol/L 
Reagent 1A (Buffer)  
 Pipes buffer, pH 7.50  50 mmol/L 
 ADPS    1 mmol/L 
 Magnesium salt   15 mmol/L 
 
Standard (Triglycerides 200 mg/dL)  
 Glycerol (Trig.equivalent)  2 g//L 
 
REAGENT RECONSTITUTION  
 The reagents are allowed to attain room temperature. The contents 
of one bottle of reagents 1 were dissolved with one bottle of reagent 1A, 
and mixed by gentles swirling and used after 5 minutes. 
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RECONSTITUTED REAGENT STORAGE & STABILITY   
    The reconstituted reagent is stable for 6 weeks when stored at 2°C-8°C. 
 
PROCEDURE 
 The samples and the reconstituted reagent were brought to room 
temperature prior to use. 
 The following general system parameters were used with this kit: 
General system parameters   
Reaction Type  : Endpoint 
Reaction Slope  : Increasing 
Wavelength   : 546 nm (520-570) 
Flowcell Temp  : 30° C 
Incubation   : 5 Min. at 37°C 
Sample Vol   : 10 μL 
Reagent Vol   : 1.0mL 
Std.Concentration  : 200 mg/dL 
Zero Setting With  : Reagent Blank 
 
The instrument was set using above system parameters. 
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The reconstituted reagent, standard and sample were dispensed in to test 
tubes as follows: 
 Blank Standard Test 
Reconstituted 
reagent 1mL 1mL 1mL 
Standard - 10μL - 
Sample - - 10μL 
 
    Incubated for 5 minutes at 37°C. Mixed and read at 546nm. The 
final colour was stable for at least 30 minutes. 
 
Linearity:    
 The method is linear up to 1000 mg/dl. 
 
Reference value for Triglycerides  
Serum/ Plasma Triglycerides  50-150 mg/dl 
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ESTIMATION OF HDL-CHOLESTEROL 
PHOSPHOTUNGSTATE METHOD       
 
PRINCIPLE 
 Chylomicrons, VLDL (Very Low Density Lipoproteins) and LDL 
fractions in serum or plasma are separated from HDL by precipitating 
with Phosphotungstic Acid and Magnesium Chloride. After 
centrifugation the cholesterol in the HDL fraction which,remains in the 
supernatant is is assigned with the enzymatic cholesterol method, using 
Cholesterol Esterase, Cholesterol Oxidase, Peroxidase and the chromogen 
4-Aminoantipyrine/Phenol. 
 
REAGENTS 
 
Reagent 1(Enzymes/Chromogen) 
 Cholesterol esterase ≥ 200 U/L 
 Cholesterol Oxidase ≥ 250 U/L 
 Peroxidase   ≥ 1000 U/L 
 4-Aminoantipyrine ≥ 0.5 mmol/L 
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Reagent 1A (Buffer): 
 Pipes buffer, pH 6.9 50 mmol/L 
 Phenol   24 mmol/L 
 Sodium Cholate  0.5 mmol/L 
 
Reagent 2 (Precipating Reagent) 
 Phosphotungstic Acid  2.4 mmol/L 
 Magnesium Chloride  39 mmol/L 
 
Standard (HDL Cholesterol 50mg/dL): 
 Cholesterol    0.5g/L 
 
REAGENT RECONSTITUTION: 
 The reagents are allowed to attain the room temperature. The 
contents of one bottle of reagent 1 is dissolved into one bottle of reagent 
1A, and mixed by gentle swirling till completely dissolved and used after 
5 minutes. 
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RECONSTITUTED REAGENT STORAGE & STABILITY 
 The reconstituted reagent was stable for 3 months when stored at 
2°C - 8°C. 
 
PROCEDURE 
 The samples, the participating reagent 2 and the reconstituted 
reagent were brought to room temperature prior to use. 
 
I. PRECIPITATION 
 The sample and precipitating reagent were dispensed into 
Centrifuge Tube as follows: 
 Test 
Sample 0.20 mL (200μL) 
Precipitating Reagent 2 0.20 mL (200μL) 
                   
Mixed well and centrifuged at 3500-4000 rpm for 10 min. The 
clear supernatant was separated immediately and determined the 
Cholesterol content as for total cholesterol estimation. 
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II. CHOLESTEROL ASSAY 
 The following general system parameters were used with this kit: 
 
General System Parameters 
Reaction Type  : End point 
Reaction Slope  : Increasing 
Wavelength   : 500 nm (492-550 nm) 
Flow cell Temp  : 30°C 
Incubation    : 5Min 37°C 
Sample Vol (Supernatant): 20 μL 
Reagent Vol   : 1.0 mL 
Std.Concentration             : 100 mg/dL (The Std. of 50 mg/dL is to be 
fed as 100 mg/dL to account for the 
dilution of sample in the precipitation 
step)      
Zero Setting With  : Reagent Blank 
The instrument was set using above system parameters. 
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The reconstituted reagent, standard and supernatant were dispensed into 
test tubes as follows: 
 Blank Standard Test 
Reconstituted 
Reagent 1 mL 1 mL 1 mL 
Standard - 20 μL - 
Supernatant - - 20 μL 
 
Incubated for 5 minutes at 37° C, mixed and read at 500 nm 
Reference value in HDL – Cholesterol:  
  Serum/ Plasma; 40 – 60 mg / dL  
ESTIMATION OF LDL CHOLESTEROL BY FRIEDEWALD 
EQUATION 
[LDL CHOLESTEROL] = [Total Cholesterol]-[HDL Cholesterol]- 
[Triglyceride/5], all concentrations are in mg/dL. 
VLDL = Triglyceride/5 
Reference Value:    
                     Serum/ Plasma LDL ; 100 – 129 mg / dL 
                        VLDL < 40 mg / dL 
Estimation of Urea : Diacetyl monoxime Method  
Estimation of Creatinine : Jaffe’s Method 
 
Urine Sugar : Benedict’s Method 
 
Urine Albumin : Heat Coagulation And Sulpho Salicylate Method 
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RESULTS AND STATISTICAL ANALYSIS 
 
 The study shows that there is increase in serum MDA levels in all 
diabetes mellitus individuals. 
 
 From table 1 we infer that the mean value of MDA is high in 
diabetic patients (Mean 4.63 μmol/L) when compared to control group 
(Mean 3.61 μmol/L) and increase is statistically significant (P = 0.0001). 
 
 Table 2 shows significant increase in MDA levels of NIDDM 
group (Mean 4.8 μmol/L) as compared to IDDM group (Mean 4.46 
μmol/L). 
 
 Table 3 shows significant elevation in MDA values along with 
increase in HbAIC values. 
  
 Table 4 shows significant elevation of Cholesterol, Triglyceride, 
LDL and VLDL in Diabetics when compared to control population. And 
significant decrease in serum levels of HDL when compared to control. 
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             Table 5 shows positive correlation between MDA and 
Cholesterol, Triglyceride, LDL, VLDL in diabetics. Negative correlation 
between MDA and HDL in diabetics. 
 
Table 6 shows  significant increase in Cholesterol, Triglyceride, 
LDL, VLDL in poorly control diabetics and decrease in HDL cholesterol. 
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DISCUSSION 
 
The mean value of plasma MDA is high in diabetic patients when 
compared to control group. 
 
 Increased lipid peroxidation in diabetes mellitus is due to excess 
formation of free radicals40.  Hyperglycaemia  in diabetics causes 
increased glycation of protein which itself act as a  source of free radicals. 
 
 Metabolic derangements in diabetes lead to an increase in 
concentration of oxidizable substrates and compromised detoxification 
pathways.   
 
 The study shows that cases on insulin as therapeutic regime 
(IDDM) had lower mean MDA level (4.46 μmol/L) as compared to those 
on oral hypoglycaemics (NIDDM) (4.8 μmol/L) indicating lesser level of 
oxidative stress in diabetics on insulin. 
 
 Considering MDA levels among cases on the basis of their 
glycaemic status, significant correlation is seen between well controlled 
and poorly controlled diabetics (both in IDDM and NIDDM). MDA is 
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higher in individuals with poor glycaemic control compared to good 
glycaemic control. 
 
 For every 1% reduction in HbAIC, one can expect 35% reduction 
in microvascular complications41.Which can be attributed to decrease in 
oxidative stress on treatment.  
          
 The metabolic parameters such as total Cholesterol, Triglycerides, 
LDL and VLDL values were more in diabetic groups than the control 
groups.  
 
 Mean value of serum HDL is decreased in diabetic group compared 
to control and decrease is statistically significant (P = 0.001). 
 
 Most common lipid disorder observed in DM is the presence of 
high plasma Triglyceride and low HDL cholesterol42. 
  
 Insulin is the principal antilipolytic regulator, acting on hormone 
sensitive lipase.Without its action as in DM, lipolysis in adipose tissue is 
increased. As a result there is increased availability of NEFAS for 
reesterification in the liver to produce more triglycerides. 
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 Lipoprotein lipase activity is less in insulin deficiency resulting in 
diminished Triglyceride clearance, impaired lipolysis of VLDL and 
reduced formation of HDL particles43. 
  
 Insulin increases the number of LDL receptor. In insulin 
deficiency, the level of LDL receptors are low, which causes the increase 
in LDL cholesterol. LDL oxidation plays an important role in 
atherogenesis44-49.  
 
The uptake of LDL by macrophage(to form foam cell)is increased by  
¾ Oxidation of  LDL 
¾ Derivitization of ApoB by glycosylation.  
¾ Reaction with Malondialdehyde.  
 
1) Oxidation of  LDL    
 Oxidised LDL has many characteristics that potentially promote  
atherogenesis, in addition to the ability to be taken up rapidly by 
macrophages to form foam cells. It is a chemoattractant for circulating 
monocytes50, both directly and also via stimulation of the release of 
monocyte chemoattractant protein-1 from endothelial cells51.  
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The chemoattractant activity of LDL resides in its lipid moiety, and 
is attributable to lysophophatidylcholine generation during the conversion 
of LDL into its oxidized form. Oxidised LDL promotes the differentiation 
of monocytes into tissue macrophages by enhancing the release  of 
macrophage colony stimulating factor from endothelial cells52, and 
inhibits the motility of resident macrophages. It is a chemoattractant to T 
cells, although not for B cells, and consequently the atherosclerotic 
plaque contains primarily monocytes and T cells.  
 
Unlike native LDL, oxidized LDL is immunogenic53 and it is also 
cytotoxic to various cell types including endothelial cells, resulting in loss 
of endothelial integrity. It inhibits tumour necrosis factor expression, 
stimulates release of interleukin-1b from monocyte macrophages, and can 
inhibit endothelial cell dependent arterial relaxation. Oxidized LDL also 
activates matrix digesting enzymes, which plays a role in plaque 
instability. 
 
2) Derivitization of ApoB by glycosylation.  
The apopotein component of LDL, apoproteinB is subject to 
glycosylation54. Glycosylation occurs by reaction of glucose with free 
amino groups of amino acids such as the epsilon amino groups of 
lysine. These amino groups are critical for the normal recognition of 
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apoprotein B by the LDL receptor and on incubation of  glycosylated 
LDL with cultured cells there was reduced uptake and degradation 
compared to control LDL due to reduced binding of glycosylated LDL 
to the LDL receptor. LDL glycosylation has been shown to affect LDL 
catabolism and  LDL receptor binding, so  prolonging the contact time 
of this highly atherogenic particle with vessel wall. Glycosylated LDL 
appers to be immunogenic,55 the glycosylated LDL/ immune complex 
could damage the arterial endothelium.  
 
3) Reaction with Malondialdehyde.  
Cholesterol deposited in the atheromatous lesion is derived from 
plasma and LDL enters the arterial wall at a rate directly related to its 
plasma concentration56. The foam cells so characteristic of atheroma 
may have their origin in macrophage monocytes  which have receptors 
for chemically altered LDL.  
 
Unlike normal LDL recptors they are not down regulated by 
increasing cellular cholesterol concentration. One type of chemically 
altered LDL taken up by macrophages57 resulting in massive 
cholesterol accumulation in those cells is malondialdehyde-modified 
LDL58.  
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An attractive hypothesis would be that malondialdehyde, a stable 
end product of the prostaglandin cascade, released from platelets or 
produced by lipid  peroxidaion at sites of injury of the arterial wall 
could lead to chemical modification of LDL rendering it recognizable 
by macrophage receptors leading to cholesterol accumulation in those 
cells. Lipid laden macrophages form the foam cell that contribute to 
development of fatty streaks and the atherosclerosis59. Oxidative stress 
occurs at an early stage in the disease pathway. It predates the 
complications . 
   
The oxidative stress in IDDM and NIDDM is evidenced by 
increased levels of plasma MDA, so intensive glycaemic control is well 
established as a standard of care for patients with diabetes achieving and 
sustaining glucose control can substantially reduce the risk of 
microvascular complications in diabetes mellitus60. Oxidative stress in 
terms of MDA is increased in NIDDM when compared to that in IDDM. 
So insulin therapy has a beneficial effect on oxidative stress. 
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CONCLUSION 
 
It is evidenced that the level of MDA is increased in both types of 
DM.There is significant increase in levels of plasma Total cholesterol, 
TGL,LDL and VLDL and significant decrease in levels of HDL in both 
types of DM. 
To conclude in the era of modern medicine diabetic complications 
demand prevention and management. 
The estimation of lipid peroxide along with lipid profile in diabetes 
mellitus is very useful as it may serve as a useful monitor to judge the 
prognosis of the patient. The detection of risk factor in the earlystage of 
the disease will help the patient to improve and reduce the morbidity rate.  
It is with this background that the ray of hope provided by the 
considerable evidence suggesting the role of prevention of increased lipid 
peroxidation could offer feasible and cost effective way to reduce the 
prevalence of  diabetic complications 
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LIPID PEROXIDATION OF PUFA TO MDA 
 
 
 
 
STANDARD CALIBRATION GRAPH FOR MDA 
 
 
 
 
MDA Values in μmol/litre  
 
                                                                            Xaxis :   1cm = 1μmol/litre 
                       Y axis:    1 cm = 0.01 od                                              
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CHOL TGL HDL LDL VLDL Urea creat
S.NO NAME AGE SEX BPmmHg
HT
cm
WT 
kg BMI
MDA
µ mol/L F PP
HbA1C
%
AB Sugar
1 Jothi 42 F 110/70 150 52 23.1 3.5 64 132 4.7 172 105 46 105 21 28 0.8 NIL NIL
2 Kannagi 41 F 110/70 148 53 24.2 3.5 81 116 4.6 161 88 42 101 18 32 0.9 NIL NIL
3 Mariyapushpam 46 F 110/70 142 38 18.9 3.6 66 110 4.8 154 92 42 104 18 20 0.6 NIL NIL
4 Kalaichelvi 49 F 120/80 146 50 23.4 3.7 90 130 5.4 184 156 46 107 31 28 0.8 NIL NIL
5 Rajeswari 40 F 120/76 149 48 21.6 3.4 72 112 4 147 94 42 86 19 18 0.7 NIL NIL
6 Arulayi 50 F 120/70 152 58 25 3.7 93 105 5.5 186 142 42 116 28 28 0.7 NIL NIL
7 Thilagavathy 36 F 120/70 153 54 23 3.7 75 100 5.6 163 99 48 95 20 30 0.8 NIL NIL
8 Mariyammal 57 F 120/80 152 56 24.2 3.6 76 104 5 156 132 42 88 26.4 22 0.7 NIL NIL
9 Minnalkodi 50 F 120/70 148 54 24.6 3.5 80 122 4.9 158 134 42 89 26.8 26 0.8 NIL NIL
10 Saroja 60 F 120/70 152 53 22.9 3.6 66 106 4.8 136 106 41 74 21 28 0.7 NIL NIL
11 Ratriyabeevi 48 F 120/80 158 60 24.1 3.6 74 112 4.8 144 110 42 80 22 26 0.8 NIL NIL
12 Vidya 33 F 120/70 148 50 22.83 3.6 106 120 4.7 126 99 46 60 20 24 0.6 NIL NIL
13 Latha 55 F 120/80 160 61 23.8 3.6 68 101 4.8 146 86 42 87 17 26 0.7 NIL NIL
14 Umamaheswari 24 F 110/70 156 48 19.7 2.9 76 116 5 138 98 43 65 20 28 0.6 NIL NIL
15 Leemarose 42 F 120/70 153 49 20.9 3.7 74 110 5.1 142 92 42 81 19.4 29 0.8 NIL NIL
16 Pankajam 53 F 130/80 148 50 22.8 3.6 80 98 4.6 156 102 42 94 20.4 28 0.7 NIL NIL
17 Kavitha 27 F 110/70 156 52 21.4 3.4 76 102 4.6 138 96 44 75 19.2 24 0.6 NIL NIL
18 Saroja 70 F 120/80 154 55 23.2 3.6 98 116 4.9 182 136 41 114 27 32 0.9 NIL NIL
URINE
CONTROL
B/Sugar mg/dl
mg/dl
CHOL TGL HDL LDL VLDL Urea creat
S.NO NAME AGE SEX BPmmHg
HT
cm
WT 
kg BMI
MDA
µ mol/L F PP
HbA1C
%
AB Sugar
URINEB/Sugar mg/dl
mg/dl
19 Malliga 22 F 110/70 148 52 23.7 3.4 76 108 4.8 124 89 46 60 18 24 0.6 NIL NIL
20 Gunasundari 40 F 110/74 153 54 23.1 3.3 76 118 4.6 136 98 44 74 20 28 0.7 NIL NIL
21 Susila 53 F 120/80 138 46 24.2 3.7 82 122 6 144 106 42 81 21.2 28 0.7 NIL NIL
22 Gunavathy 30 F 110/70 159 60 23.8 3.4 62 84 4.3 132 98 44 68 20 24 0.7 NIL NIL
23 Sumathy 41 F 110/70 162 60 22.9 3.6 74 106 4.9 154 102 43 91 20.4 24 0.7 NIL NIL
24 Meenatchi 38 F 120/70 156 57 23.4 3 72 112 4.8 130 96 42 69 19.2 26 0.6 NIL NIL
25 Rajathi 48 F 120/76 154 56 23.6 3.7 80 116 5.2 144 104 45 76 23 28 0.7 NIL NIL
26 Rengasamy 65 M 130/80 162 64 24.4 3.7 86 125 5.3 170 128 40 63 25.6 29 0.9 NIL NIL
27 Rajendran 51 M 120/80 153 60 25.6 3.6 87 98 4.9 141 117 42 76 23 28 0.8 NIL NIL
28 Shankaran 42 M 130/80 165 68 25 3.6 78 108 4.8 144 109 44 78 21.8 28 0.8 NIL NIL
29 Sambatham 65 M 110/70 150 56 24.8 3.5 62 105 4.6 148 86 40 91 17 26 0.8 NIL NIL
30 Padmanaban 37 M 116/76 153 55 23.5 3.6 72 108 4.9 150 98 46 85 19.6 27 0.7 NIL NIL
31 Sundaram 50 M 130/80 154 62 26.1 3.7 90 116 5.4 160 110 42 96 22 28 0.9 NIL NIL
32 Swaminathan 64 M 130/80 160 64 25 3.6 78 118 4.7 170 132 41 113 26.4 30 0.9 NIL NIL
33 Ramu 38 M 120/70 148 54 24.6 3.6 76 104 4.6 146 134 43 77 26.8 22 0.7 NIL NIL
34 Murali 44 M 120/70 160 62 24.2 3.6 90 108 5.3 150 96 43 88 19 28 0.8 NIL NIL
35 Logeshwaran 33 M 120/70 158 52 20.8 3.5 76 98 4.7 136 98 45 71 20 24 0.6 NIL NIL
36 Vijay Anand 32 M 120/70 148 50 22.8 3.5 74 112 4.7 154 102 44 90 20.4 26 0.7 NIL NIL
37 Deva 21 M 110/70 156 54 22.2 3.4 68 106 4.4 132 84 45 70 17 24 0.6 NIL NIL
CHOL TGL HDL LDL VLDL Urea creat
S.NO NAME AGE SEX BPmmHg
HT
cm
WT 
kg BMI
MDA
µ mol/L F PP
HbA1C
%
AB Sugar
URINEB/Sugar mg/dl
mg/dl
38 Valluvan 36 M 120/70 158 57 22.8 3.6 78 120 4.6 136 88 44 74 18 28 0.7 NIL NIL
39 Karthikeyan 27 M 110/70 154 56 23.6 3.6 77 118 4.6 146 120 46 76 24 22 0.7 NIL NIL
40 Johnbritto 25 M 110/70 156 58 23.8 3.7 80 113 5 144 88 43 83 18 23 0.6 NIL NIL
41 Ayyadurai 63 M 130/80 158 60 24.1 3.8 82 124 5.1 155 107 44 90 21 30 0.9 NIL NIL
42 Ramasamy 50 M 120/70 156 60 24.6 3.4 68 108 4.4 160 124 46 90 24.8 30 0.8 NIL NIL
43 Muthusamy 70 M 130/80 158 56 22.4 3.6 90 124 5.3 172 126 42 105 25.2 36 0.9 NIL NIL
44 Velu 56 M 120/80 154 51 21.5 3.6 86 114 5.1 147 108 43 83 21.6 26 0.8 NIL NIL
45 Chandran 35 M 120/70 164 63 23.5 3.6 88 128 4.9 138 112 44 72 22.2 24 0.7 NIL NIL
46 Jaganathan 55 M 120/80 162 60 22.9 3.8 78 126 4.8 154 128 42 86 26 28 0.8 NIL NIL
47 Gajendran 24 M 116/70 160 56 21.8 3.2 72 112 4.7 130 98 45 65 19.6 26 0.6 NIL NIL
48 Ramamoorthy 53 M 120/80 156 58 23.8 3.3 68 110 4.4 152 106 42 89 21 24 0.7 NIL NIL
49 Rengaraj 60 M 120/80 149 53 23.8 3.5 78 114 4.6 154 96 43 92 19 34 0.8 NIL NIL
50 Elavarasan 47 M 120/80 156 59 24.2 3.4 118 118 4.4 147 98 45 82 19.6 24 0.8 NIL NIL
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